Form 4: Saba Capital Management Reduces Stake in BlackRock Capital Allocation Term Trust
SEC Form 4
Saba Capital Management sold 161,654 shares of BlackRock Capital Allocation Term Trust (BCAT) at $15.49 per share on March 3, 2025, reducing their holdings.
Summary
- On March 3, 2025, Saba Capital Management, L.P. sold 161,654 shares of BlackRock Capital Allocation Term Trust (BCAT).
- The sale price was $15.49 per share.
- Following the transaction, Saba Capital Management's beneficial ownership in BCAT is 12,313,575 shares.
- Boaz Weinstein, also listed as a reporting person, is associated with Saba Capital Management.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a transaction. It doesn't inherently convey positive or negative sentiment, but a large sale could be interpreted neutrally to slightly negatively depending on the context.
Industry Context
Hedge funds like Saba Capital Management frequently adjust their positions in closed-end funds like BCAT to manage their portfolios and capitalize on market opportunities.
Stakeholder Impact
- The sale of shares by a major holder like Saba Capital Management could potentially influence the short-term trading price of BCAT.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of transaction: Saba Capital Management sold shares of BCAT. |
| 03/04/2025 | Date of signature for the Form 4 filing by Zachary Gindes and Boaz Weinstein. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.